A step-by-step approach to study the influence of N-acetylation on the adjuvanticity of N,N,N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine. 2012

Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.

Recently we reported that reacetylation of N,N,N-trimethyl chitosan (TMC) reduced the adjuvant effect of TMC in mice after intranasal (i.n.) administration of whole inactivated influenza virus (WIV) vaccine. The aim of the present study was to elucidate the mechanism of this lack of adjuvanticity. Reacetylated TMC (TMC-RA, degree of acetylation 54%) was compared with TMC (degree of acetylation 17%) at six potentially critical steps in the induction of an immune response after i.n. administration in mice. TMC-RA was degraded in a nasal wash to a slightly larger extent than TMC. The local i.n. distribution and nasal clearance of WIV were similar for both TMC types. Fluorescently labeled WIV was taken up more efficiently by Calu-3 cells when formulated with TMC-RA compared to TMC and both TMCs significantly reduced transport of WIV over a Calu-3 monolayer. Murine bone-marrow derived dendritic cell activation was similar for plain WIV, and WIV formulated with TMC-RA or TMC. The inferior adjuvant effect in mice of TMC-RA over that of TMC might be caused by a slightly lower stability of TMC-RA-WIV in the nasal cavity, rather than by any of the other factors studied in this paper.

UI MeSH Term Description Entries
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000107 Acetylation Formation of an acetyl derivative. (Stedman, 25th ed) Acetylations
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations

Related Publications

Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
December 2019, Artificial cells, nanomedicine, and biotechnology,
Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
November 2008, International journal of pharmaceutics,
Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
January 2007, Vaccine,
Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
May 2018, Vaccine,
Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
April 2019, International journal of molecular sciences,
Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
July 2020, Carbohydrate research,
Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
May 2010, Journal of controlled release : official journal of the Controlled Release Society,
Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
November 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
July 2020, International journal of biological macromolecules,
Rolf J Verheul, and Niels Hagenaars, and Thomas van Es, and Ethlinn V B van Gaal, and Pascal H J L F de Jong, and Sven Bruijns, and Enrico Mastrobattista, and Bram Slütter, and Ivo Que, and Jacco G M Heldens, and Han van den Bosch, and Harrie L Glansbeek, and Wim E Hennink, and Wim Jiskoot
August 2012, Carbohydrate polymers,
Copied contents to your clipboard!